EGFR and prostate cancer: For KEGG pathway analysis, both of the targets were particularly enriched in proteoglycans in cancer, microRNAs in cancer, prostate cancer, EGFR tyrosine kinase inhibitor resistance, and endocrine resistance (P < 0.05).